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ABSTRACT
International Journal of Exercise Science 14(2): 727-741, 2021. Huperzine A has shown the ability to

acutely improve cognitive function in certain populations, and therefore is commonly added to pre-workout
supplements. However, its effects have not been studied in exercise-trained individuals. OBJECTIVE: We
hypothesized that acute consumption of huperzine A would improve cognitive function during exercise, which
may be beneficial for exercise performance. METHODS: From January to April, 2018, 15 exercise-trained
individuals (11 women [height 166 ± 2 cm, weight 60.5 ± 3.0 kg] and 4 men [height 173 ± 4 cm, weight 82.0 ± 11.0
kg], BMI 23.5 ± 1.4 kg/m2, age 30.4 ± 3.6 years) were studied in a double blind randomized-sequence cross-over
study, in which they underwent tests for cognitive function (digit span, verbal/word fluency, and Stroop),
neuromuscular performance (sharpened Romberg and dart throwing), and exercise performance (estimated
aerobic capacity, hand-grip strength, vertical jump, and push-up) after acute ingestion of huperzine A (200 mcg) or
placebo. One week separated the two trials. RESULTS: No measures of cognitive function differed between placebo
and huperzine A trials (all p ≥ 0.296). Heart rates (157 ± 4 vs. 158 ± 4 bpm; p = 0.518) and ratings of perceived exertion
(13.7 ± 0.56 vs. 13.9 ± 0.61; p = 0.582) did not differ between placebo and huperzine A trials, respectively. Ratings of
subjective difficulty post-exercise (0-10 scale) were significantly higher (5.7 ± 0.38 vs. 6.8 ± 0.38; p = 0.002) in the
huperzine A trial than the placebo trial. No differences were observed for neuromuscular or exercise performance
measures between groups (all p ≥ 0.497). CONCLUSIONS: Huperzine A does not enhance cognitive function during
exercise despite it being marketed as a cognitive enhancer. Because of its inability to enhance cognitive function, its
inclusion in pre-workout supplements warrants reconsideration. Other more practical and effective strategies
should be considered.

KEY WORDS: Aerobic exercise, cognitive performance, sports nutrition, cardiorespiratory
fitness, acetylcholinesterase inhibitors, ergogenic aid
INTRODUCTION
The use of supplements as ergogenic aids has become increasingly popular among exercisetrained individuals across many sports and competition levels (20). One of the most popular
forms of these supplements is energy drinks, which were reported to be used by 73% of division
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I collegiate athletes; one of the main reasons for consuming these drinks was to “provide energy
during practice” (15). Many energy drinks and supplements contain multiple ingredients to
which enhanced “energy” and ergogenic effect could be attributed. This makes it difficult to
determine which ingredients are responsible any observed benefits. Although some ingredients
in sports supplements and energy drinks, such as carbohydrate and caffeine, have been
extensively studied for ergogenic effects, little or no scientific evidence exists for other common
ingredients.
Huperzine A is an ingredient found in ~11% of multi-ingredient pre-workout supplements (1).
It was originally isolated from the moss Huperzia serrata and has been used in Traditional
Chinese Medicine to promote circulation, fever reduction, anti-inflammatory effects, and for
analgesic purposes (17). Huperzine A is marketed in the United States as a cognitive enhancing
supplement and is available over-the-counter. Some evidence suggests that huperzine A
modestly improves cognitive function in patients with Alzheimer’s disease and dementia (34),
possibly through its potent inhibition of acetylcholinesterase (36). Huperzine A may also acutely
enhance cognitive function in young, healthy adults (24, 35). Presumably based on these studies,
huperzine A has been added to sports supplements to provide mental and physical “energy”
for exercise training, which would be appealing to athletes and other exercise enthusiasts.
Because exercise-induced mental fatigue affects physical performance (16), it is also conceivable
that huperzine A could also have ergogenic effects. Despite these appealing possibilities, no
studies have evaluated the effects of huperzine A on mental (cognitive) function during exercise
or on exercise performance. In this context, the purpose of this study was to use a double blind,
randomized-sequence, placebo-controlled crossover trial to evaluate the hypothesis that
huperzine A enhances cognitive function during exercise and reduces perception of effort. A
secondary aim was to evaluate the effects of huperzine A on several neuromotor tasks (e.g.,
balance) and on exercise performance.
METHODS
Participants
Exercise-trained men and women aged 18-60 (30.4 ± 3.6) years old from the greater Saint Louis
area were recruited. Candidates were required to be exercise-trained, which was defined as
moderate to vigorous intensity endurance exercise (i.e., brisk walking, running, cycling, etc.), at
least three days per week, for at least 20-minutes per session, for at least six months prior to this
study. Resistance training did not contribute to the definition of exercise-trained for the
purposes of this study. Medical history, medication use, and diet history were used in
conjunction with the American College of Sports Medicine’s risk classification algorithms to
identify and exclude those individuals that required medical clearance to participate in vigorous
exercise (14). All of the participants provided informed written consent to participate in the
study, which was reviewed and approved by the Saint Louis University Institutional Review
Board. The trial was registered at ClinicalTrials.gov (identifier: NCT03445104). This research
was carried out fully in accordance to the ethical standards of the International Journal of
Exercise Science (25).
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Protocol
The study was conducted in a university setting and utilized a double blind, crossover design.
An initial session was used to familiarize participants with the procedures and obtain baseline
measures. The participants underwent two experimental trials in which they received huperzine
A or placebo in randomized sequence. The randomization scheme was counter balanced with
blocking (2 subjects per block; www.randomization.com) and allocation was performed by
personnel not involved in data collection to maintain participant and investigator blinding
(Figure 1).

Figure 1. Study Design. The study was a randomized sequence cross-over trial in which participants underwent
outcomes testing on one occasion after oral supplementation with Huperzine A and on another occasion after
taking a placebo. The sequence for treatment administration (Huperzine A vs. placebo) was randomly assigned for
each participant.

Huperzine A (200 mcg, Swanson®, Fargo, North Dakota) and placebo capsules were
administered in a single oral dose. The dose of Huperzine A used is comparable to previous
research (33). Placebo capsules consisted of rice flour and the capsules were identical in size and
appearance. The participants ingested the capsules with 250 mL of water 30-45 minutes before
exercise was initiated. Previous work has identified that orally ingested huperzine A appears in
the blood within 15-minutes and reaches peak levels by 60-minutes (22).
Enrolled participants underwent an initial visit to be familiarized with diet, exercise, and sleep
control procedures, exercise and cognitive function tests, exercise equipment, and
supplementation procedures. Outcome tests were performed for familiarization purposes and
for non-intervention baseline measures.
The participants returned within one week of the initial session for the first study trial. During
this session, participants received either huperzine A or placebo and underwent testing. After
one week, participants returned for the second study trial, and based on what they received
during the first session, received either huperzine A or placebo before undergoing the same
testing. Mood assessment was performed before and after exercise, RPE and HR were measured
periodically throughout exercise, cognitive function tests were performed during the last 10minutes of exercise. All remaining tests were performed following exercise. These outcome
measures are described in further detail below.
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During the first experimental session, the endurance exercise task consisted of a fatigue inducing
protocol using a treadmill (PPS 55, Woodway, Inc., Waukesha, WI). The task involved an initial
stepwise increase in work rate until 70% of heart rate reserve (HRR) was reached [70% HRR =
0.70 x (maximal heart rate – resting heart rate) + resting heart rate]. Age-predicted maximal HR
was predicted via 208 – 0.7 x age in years (30). An additional 30 minutes of steady state exercise
was then performed at this work rate. Initially, the treadmill was set to a speed of two miles per
hour (MPH) at 0% grade. Speed was increased by 0.5 MPH every three minutes until the
participant reached a self-defined “brisk” pace. Participants were permitted to walk or to run
based on their perception of “brisk”. From there on, percent grade was increased by 2% until
70% HRR was reached (Figure 2). The speed and grade at which 70% HRR was reached was
used during the second experimental session (19). Total estimated time of this task was 35-45
minutes; exercise bouts of this duration have been shown to impair cognitive function in past
studies (23, 31).

Figure 2. Treadmill exercise protocol. During each participant’s first study trial, exercise was initiated at 2.0 mph
and 0% grade for 3 minutes, followed by 0.5 mph speed increments every 3 minutes until the participant reached
a self-described “brisk” pace; thereafter, grade was increased 2 percentage points every 3 minutes until 70% of
heart rate reserve (HRR) was attained. The work rate that elicited 70% HRR was then performed for 30 minutes
and cognitive function tests were performed during the last 10 minutes of this period. During each participant’s
second study trial, the speed and grade used during the first protocol were replicated exactly to ensure that the
external work rate for the two study trials was matched.

Cognitive function tests that were performed include: digit span (forward), verbal
fluency/word fluency, and the Stroop test. These tests have been utilized to assess cognitive
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function through different cognitive domains during exercise in the past (4). During the study
trials, these tests were implemented with 10 minutes remaining in the endurance-exercise task.
By using a randomization process, the test sequence was homogenized to ensure that the test
sequence differed every time a given participant was tested.
The digit span (forward) test was used as a measure of working memory (4). Variations of this
test have been used to assess cognitive function in children and adults (21, 28). During a period
of two minutes, the participants were presented with a series of digits at a rate of one digit per
second and were required to repeat them verbatim. If they succeeded, they were presented with
a longer series by one digit. The length of the series continued to increase by one digit until the
participant failed to successfully repeat the digit span on two consecutive attempts or until the
two-minute time limit was reached. The longest series the participant was able to recall was
recorded as their digit span score.
Letter verbal fluency and category verbal fluency were used as measures of verbal ability and
executive control (4). For letter verbal fluency, participants were instructed to generate words
beginning with F, A, S, B, H, or R. Each participant was randomly assigned a different letter at
each session. Participants were given one minute to name as many words as they could,
beginning with the letter they were assigned. The total number of words named within one
minute was recorded as the participant’s letter fluency score. For category verbal fluency,
participants were instructed to produce as many words as they could for a particular category
(e.g., animals, items of clothing, boys’ names, or girls’ names) within one minute. Each
participant was randomly assigned to a different category each session. The total number of
words named within one minute was recorded as the participant’s letter fluency score. A similar
protocol was used by Nocera and colleagues to assess the impact of exercise on executive
function in elderly adults (26).
The Stroop test was used as a measure of information processing (4). Participants were exposed
to color names in a font color that did not match the color name. They were instructed to name
the color of the font and to ignore the color name (e.g., if the word green was presented to them
in red font, the goal was to say “red” and ignore the word green). The participants had two
minutes to complete this task. The sum of correctly identified stimuli was recorded as their
Stroop score. This test is a modified version of the Stroop effect task originally developed by
Stroop (29).
The RPE scale is used to allow the exerciser to subjectively rate their effort during exercise. The
scale can also be used to indicate impending fatigue. Participants were asked to report their RPE
on a scale of 6 to 20 (6 being no exertion at all, 20 being maximal exertion) at 5-minute intervals
during the endurance exercise task (13). Immediately prior to the endurance exercise task,
participants were asked to rate their confidence regarding the task on a scale from 0-10.
Immediately following the endurance exercise task, participants were asked about the
ease/difficulty of the task.
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Following endurance exercise, participants’ hand-grip strength and vertical jump height were
used as measures of muscular strength. Grip strength was measured using a hydraulic hand
grip dynamometer (27) (model J00105, Lafayette Instrument, Inc., Lafayette, IN). Both arms were
used for testing while bent at a right angle with the elbow at the participants’ side. Participants
were instructed to squeeze the dynamometer handle with maximal effort for five-seconds three
separate times, with the best of the three results being recorded. The vertical jump test was
conducted by instructing participants to stand side onto wall and to jump from a standing
position using their arms and legs to propel themselves upward. Their fingertips were covered
in chalk, which they used to mark the wall at the highest point of the jump. The highest of three
jumps was recorded (5).
A push-up test standardized through the ACSM was used as a measure of muscular endurance
following handgrip and vertical jump protocol. To begin, men started in the standard “down”
position, while women started in the modified “knee push-up” position. Hands were pointed
forward and under the shoulder with the back straight and head up. The participants were then
instructed to raise their body by straightening their elbows before returning to the down
position. For this test, the back must remain straight at all times, the participant must continue
downward until their chin touches the floor or a mat, and the participant must fully straighten
their arms during each repetition. The test was stopped when the participant strained forcibly
or was unable to maintain proper form. The maximum number of pushups without form
breakdown was recorded (13).
Aerobic capacity was calculated via standard techniques (37) and was used to predict maximal
oxygen uptake (VO2max) during treadmill running. A regression equation was generated for
each participant based on their resting HR, submaximal exercise HR, and predicted oxygen
uptake (VO2). Their resting and exercise HRs were measured as described above, while their
resting VO2 was assumed to be 3.5 mL/kg/minute. VO2 at age-predicted maximal HR was
calculated using the subsequently generated regression equation, where age-predicted maximal
HR = 208 – 0.7 x age in years. This was considered VO2max (30).
Dart throwing was used as a measure of hand-eye coordination following the muscular
endurance task. Modelled after previous dart throwing procedures used in previous research,
the dartboard consisted of ten concentric circles. The board was positioned in accordance with
international standards; the bull’s-eye was 1.73 m from the floor while the throwing line was
2.37 meters away from the board. The score ranged on a scale from 0-10 (0 being off of the board,
10 being a bull’s-eye). Participants completed three rounds of three throws. The total score from
all throws was the recorded score (37).
The Sharpened Romberg test (SR) was used as a measure of balance performance. The
participants were asked to remove their shoes and stand with their feet in tandem position (heel
to toe), their arms crossed over their chest, and the palms of their hand on the opposite shoulder.
They were first asked to stand quietly with their eyes open and then with their eyes closed. They
were instructed to attempt to maintain this position for 60-seconds. If they were unable to do so,
they were given up to three additional attempts. The sum of each trial was recorded. If a score
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of 60-seconds was reached at any attempt the subsequent attempts were forgone and given the
score of 60. Study personnel were nearby to ensure safety of the participant should they have
fallen (18).
During an initial meeting the participants were instructed regarding keeping a 24-hour food log
before both testing days. The 24-hour food log prior to the first session served as a guide to
replicate dietary intake prior to the second session. Participants were instructed to continue their
current training regimens but were instructed to avoid strenuous activity 24 hours prior to each
testing session. Additionally, participants were asked to keep a record of their sleep patterns
prior to testing (i.e. bed time, wake up time, and any naps). If participants were unable to
duplicate dietary, exercise, or sleep patterns from their first visit for their second visit, the
principal investigator used subjective clinical judgement to determine if the severity of
difference warranted rescheduling of the participant.
Resting heart rate was measured via manual palpation of the radial artery for one minute. A
wristwatch-type heart rate monitor (Polar RS200, Polar Electro Oy, Kempele, Finland) was used
to monitor exercise heart rate, which was recorded at intervals of 5-minutes during endurance
exercise.
Statistical Analysis
A statistical power analysis was performed (G*Power software, version 3.1.5, University of Kiel,
University of Dusseldorf, and University of Mannheim, 157 Germany) based on the following
inputs: two-tailed paired t-test, alpha = 0.05, desired power = 0.80, sample size = 15 subjects.
The results indicated that a standardized effect size of 0.78 (i.e., large effect) would be detectable.
15 subjects were recruited and enrolled in the study.
A paired-sample t-test with alpha set to p ≤ 0.05 for statistical significance was used to analyze
the data. Outcomes measured during the first and second experimental sessions were compared
to each other. The participants were compared to themselves during previous sessions, so a
paired sample t-test was used to calculate the difference between the sessions. Data was
presented as means ± SE. Data analyses was performed with Microsoft Excel and Cohen’s effect
size analyses were performed using an online calculator
(http://www.campbellcollaboration.org/escalc/html/EffectSizeCalculator-Home.php).
RESULTS
Fifteen women (n = 11) and men (n = 4) were enrolled and completed the entire study (Table 1).
Age of the participants was in the lower end of the targeted range. Thirteen of the participants
were in the normal range for BMI, while two were in the overweight category, and one was in
the obese category. All participants were exercise trained, defined as participating in moderate
to vigorous intensity endurance exercise ≥ 3 days/week, for ≥ 20-minutes/session, for ≥ 6
months. On average, participants self-reported participating in moderate exertion endurance
exercise 5 days/week for 67 min/session (Table 1).
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Table 1. Subject Characteristics
Gender
Men
4 (27%)
Women
11 (73%)
Age, years
30.4 ± 3.6
Height, cm
Men
173 ± 4
Women
166 ± 2
Body mass, kg
Men
82.1 ± 11.0
Women
60.5 ± 3.0
BMI, kg/m2
23.5 ± 1.4
Habitual exercise modes
Endurance exercise
15 (100%)
Endurance & strength exercise
10 (67%)
Habitual exercise frequency, sessions/week
5±0
Habitual exercise duration, min (all modes combined)
67 ± 7
Habitual exercise intensity, sessions/week
Light exertion
1 (7%)
Moderate exertion
15 (100%)
Hard exertion
5 (33%)
Baseline cognitive function tests
Digit span
6.7 ± 0.3
Letter fluency
17.3 ± 1.1
Category fluency
24.3 ± 1.7
Stroop
83.5 ± 3.5
Predicted VO2max, mL/kg/min
Men
53.7 ± 2.6
Women
45.4 ± 3.0
Values are counts (%) or means ± SE. Estimates of exercise frequency, duration, and intensity include all modes
of exercise.

Digit span did not change from rest to exercise in either the placebo trial (5.22 ± 5.43%, p = 0.510)
or huperzine A trial (5.04 ± 4.69%, p = 0.458). Furthermore, there was no difference (p = 0.96) in
percent change (Figure 3) observed between placebo (5.22 ± 5.43%) and huperzine A (5.04 ±
4.69%) trials for digit span. Letter fluency tended to improve from rest to exercise in the placebo
trial (22.93 ± 10.02%, p = 0.076) and improved significantly in the huperzine A trial (28.46 ±
10.68%, p = 0.018). However, there was no significant difference (p = 0.49) in percent change
observed between placebo (22.93 ± 10.02%) and huperzine A (28.46 ± 10.68%) trials for letter
fluency. Category fluency did not improve from rest to exercise in either the placebo (8.86 ±
9.80%, p = 0.756) or huperzine A trial (0.53 ± 8.00%, p = 0.609). Further, there was no significant
difference (p = 0.39) in percent change observed between placebo (8.86 ± 9.80%) and huperzine
A (0.53 ± 8.00%) trials for category fluency. Stroop tended to improve from rest to exercise in the
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placebo trial (9.91 ± 4.30%, p = 0.067) and improved significantly in the huperzine A trial (11.95
± 4.32%, p = 0.022). However, there was no significant difference (p = 0.59) in percent change
observed between the placebo (9.91 ± 4.30%) and huperzine A (11.96 ± 4.32%) trials for the
Stroop test.

Percent Change from Baseline

50
45

p = 0.49

40

*

Placebo trial
Huperzine A trial

35
30
25

p = 0.39
p = 0.59

20
p = 0.96

*

15
10
5
0
Digit Span

Letter Fluency

Category Fluency

Stroop

Figure 3. Average percent change of cognitive function task performance from the resting baseline to exercise
during the study trials.

The study results were also analyzed by using standardized effect sizes (Cohen’s d) to gain
insights about the effects of huperzine A on cognitive function. Results from these analyses were
mixed, suggesting no treatment effects on digit span performance (d = 0.03), small to moderate
beneficial effects of huperzine A on letter fluency (d = 0.37) and Stroop tests (d = 0.29), and small
to moderate detrimental effects of huperzine A on category fluency (d = 0.46).
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Figure 4. Average heart rate and rating of perceived exertion during 5-minute intervals during a 30-minute steady
state treadmill exercise.

Average RPE did not differ (p = 0.582) between the placebo (13.7 ± 0.56) and huperzine A (13.9
± 0.61) trials. RPE did not different significantly at any 5-minute interval during the treadmill
exercise (all p ≥ 0.12; Figure 4). Average ratings of pre-exercise confidence (0-10 scale) did not
differ (p = 0.546) between the placebo (8.2 ± 0.45) and huperzine A (8.3 ± 0.39) trials. Average
ratings of subjective difficulty post-exercise (0-10 scale) differed significantly (p = 0.002) between
the placebo (5.7 ± 0.38) and huperzine A (6.8 ± 0.38) trials (Figure 5).
10

Subjective Difficulty Rating

9
8
7
6

6.8 ± 0.4
5.7 ± 0.4

5
4
3

p = 0.002 between trials
2
Placebo

Huperzine A

Figure 5. Mean and subject-level post-exercise subjective difficulty ratings following the 30-minute treadmill
exercise.
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Measures of neuromuscular performance included the sharpened Romberg balance test and a
dart-throwing test. Average balance time did not differ (p = 0.629) significantly between placebo
(113 ± 16.4 min) and huperzine A (121 ± 17.1 min) trials. Also, average dart-throwing scores did
not differ (p = 0.676) between placebo (49.4 ± 3.2) and huperzine A (50.0 ± 2.7) trials.
Table 2. Cognitive Function & Exercise Performance in response to Placebo and Huperzine A
Placebo
Huperzine A
(n = 15)
(n = 15)
Cognitive Function
Digit span score
6.9 ± 0.3
6.9 ± 0.2
Letter fluency score
20.1 ± 1.0
20.9 ± 0.9
Category fluency score
24.9 ± 1.4
23.3 ± 1.4
Stroop score
92.1 ± 3.7
94.9 ± 4.6
Treadmill Exercise
Aerobic Capacity, mL/kg/min
47.6 ± 2.5
47.4 ± 2.0
Heart Rate, bpm
157 ± 4
158 ± 4
RPE
13.7 ± 0.56
13.9 ± 0.61
Confidence & Mood
Confidence Pre-Exercise (0-10)
8.2 ± 0.45
8.3 ± 0.39
Difficulty Post-Exercise (0-10)
5.7 ± 0.38
6.8 ± 0.38
Neuromuscular Performance
Balance, min
113 ± 16.4
121 ± 17.1
Darts score
49.3 ± 3.2
50.0 ± 2.7
Muscular Strength & Endurance
Handgrip Strength, kg
61.5 ± 4.6
61.3 ± 4.3
Vertical Jump Test, inches
16.4 ± 1.1
16.6 ± 1.1
Push-Ups
38.2 ± 5.0
37.7 ± 4.0
Values are means ± SE. p-values are from paired t-tests. p < 0.05 was considered significant.

p-value
1.000
0.498
0.296
0.345
0.856
0.518
0.582
0.546
0.002
0.629
0.676
0.895
0.497
0.795

During the treadmill exercise, estimated aerobic capacity did not differ (p = 0.856) between
placebo (47.6 ± 2.5 mL/kg/min) and huperzine A (47.4 ± 2.0 mL/kg/min) trials. Also, average
HR did not differ (p = 0.518) between placebo (157 ± 4 bpm) and huperzine A (158 ± 4 bpm) trials
(Figure 4). Performance on handgrip strength (p = 0.895), vertical jump (p = 0.497), and push-up
(p = 0.795) tests did not differ between trials (Table 2).
DISCUSSION
Huperzine A is included as an ingredient in many pre-workout nutritional supplements that are
advertised to “increase energy levels” during exercise. While the justification for including
huperzine A in these supplements is not clear, it may be linked with studies that showed
enhanced cognitive function, even though these were studies of patients with Alzheimer’s
disease and dementia (34). Therefore, we proposed that huperzine A may acutely augment
cognitive function during a bout of endurance exercise. The results of this study do not support
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this hypothesis as evidenced by no significant differences in cognitive function between study
trials.
Further analysis reveals the perceived difficulty of the endurance exercise was rated an average
of 1.1 points (0-10 scale) more difficult during the huperzine A trial than the placebo trial (Figure
5). This coupled with RPE and HR data (Figure 4) suggest huperzine may have made exercise
more difficult. To our knowledge this is the first study to investigate huperzine A’s ability to
enhancing cognitive function during exercise in any population, despite its fairly common
inclusion in pre-workout supplements (1). Additionally, measures of neuromuscular and
exercise performance did not differ between the two study trials.
Huperzine A is a competitive inhibitor of AChE with various properties that imply its usefulness
as a cognitive enhancer (34, 36). Huperzine A forms two hydrogen bonds within the gorge of
AChE and has a longer dissociation time than what is typical of most therapeutic AChEIs (6, 32).
Orally ingested huperzine A appears in the blood within 15-minutes and reaches peak levels by
60-minutes while remaining in the system for at least 12-hours (22). These properties seem to
warrant huperzine A’s use as a cognitive enhancer. Other AChEIs have been shown to attenuate
transient decline of cognitive function associated with sleep deprivation (7, 35). Therefore, we
speculated that it would provide beneficial effects on cognitive function during exercise.
It is unclear why evidence for improved cognitive function was not observed in this study, but
there are possibilities that warrant discussion. First, there was no decline in cognitive function
observed from baseline to exercise. Other AChEIs have demonstrated the ability to attenuate
transient cognitive decline associated with sleep deprivation (7, 11). Had the participants
experienced transient cognitive decline during exercise, it is possible huperzine A could have
attenuated such decline. Second, this study used an acute dose of huperzine A. Previous
research showing improvement of cognitive function with AChEIs used chronic dosing (2, 3).
Perhaps chronic dosing of huperzine A may have offered a benefit in terms of cognitive function.
Third, it is likely that the mechanism for cognitive decline in Alzheimer’s disease and dementia
is different than that of any cognitive decline that would be associated with exercise.
The double-blind, placebo controlled, cross-over design study design is clearly a strength of this
study. However, the small sample size (n = 15) might be viewed as a limitation, contributing to
low statistical power. Therefore, in addition to more conventional statistical analyses, the results
were also evaluated by calculating Cohen’s effect size estimates. Results from these analyses
were mixed, with one cognitive function outcome showing no treatment effect (letter fluency
test), others showing small to moderate beneficial effects of huperzine A (letter fluency and
Stroop tests), and another showing detrimental effects of huperzine A (category fluency test). In
aggregate these supplemental analyses do not provide definitive information about the effects
of huperzine A but do suggest that future trial with larger sample sizes may be warranted.
This study also had other limitations. Because nutritional supplements are not subject to the
same regulations as therapeutic medications, and because we did not analyze the content of the
supplements used in our study, we cannot confirm the potency and purity of the supplement
International Journal of Exercise Science

738

http://www.intjexersci.com

Int J Exerc Sci 14(2): 727-741, 2021
used in this study. However, we did select a brand that underwent voluntary third-party
certification to mitigate this limitation. In the present study, the authors did not perform any
analyses regarding the effects of the supplement relative to body size or body mass; this may be
a potential avenue for researchers to pursue in the future. Further, this exercise protocol did not
produce fatigue sufficient enough to cause transient cognitive function decline. Past research
utilizing protocols of higher intensity and longer duration have produced fatigue sufficient to
cause cognitive decline during exercise (8, 9, 12, 23). It may be speculated, had the protocol in
the present study produced cognitive function decline, huperzine A may have been able to
ameliorate the decline.
In conclusion, the results from this study indicate that huperzine A does not have clear effects
on cognitive function during exercise in exercise trained individuals. However, small effects
(positive or negative) cannot be definitively ruled out and larger trials may be warranted.
Huperzine A is a common component of pre-workout supplements, presumably for enhancing
mental function during exercise; however, based on our data, it is not likely to provide such
benefits. A practical implication of these findings is that athletes and other exercisers should be
advised to seek other approaches for maintaining or enhancing cognitive function during
exercise.
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